Paysign/$PAYS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Paysign
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.
- Ticker
- $PAYS
- Sector
- Finance
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Henderson, United States
- Website
- www.paysign.com
Paysign Metrics
BasicAdvanced
$829M
56.78
$0.26
0.83
-
Price and volume
Market cap
$829M
Beta
0.83
52-week high
$16.15
52-week low
$3.08
Average daily volume
887K
Financial strength
Current ratio
1.139
Quick ratio
0.527
Long term debt to equity
0.08
Total debt to equity
0.095
Profitability
EBITDA (TTM)
25.547
Gross margin (TTM)
61.00%
Net profit margin (TTM)
15.67%
Operating margin (TTM)
15.65%
Effective tax rate (TTM)
21.58%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
3.88%
Return on equity (TTM)
30.82%
Valuation
Price to earnings (TTM)
56.775
Price to revenue (TTM)
8.044
Price to book
13.78
Price to tangible book (TTM)
23.8
Price to free cash flow (TTM)
11.981
Free cash flow yield (TTM)
8.35%
Free cash flow per share (TTM)
1.226
Growth
Revenue change (TTM)
46.84%
Earnings per share change (TTM)
115.66%
3-year revenue growth (CAGR)
33.40%
10-year revenue growth (CAGR)
27.66%
3-year earnings per share growth (CAGR)
135.38%
10-year earnings per share growth (CAGR)
17.84%
What the Analysts think about Paysign
Analyst ratings (Buy, Hold, Sell) for Paysign stock.
Analyst projections of the future price of Paysign stock.
Bulls say / Bears say
Pharma patient-affordability is scaling quickly: revenue rose 88.9% year on year in Q2 2026, alongside 51 net programme additions and 54% more claims processed. That gives Paysign a strong growth engine beyond its established plasma business. (SEC)
Management raised its 2026 outlook after Q2, projecting revenue of $114–117 million and adjusted EBITDA of $35–38 million. It also expects gross margin of 62–63%, pointing to continued growth and operating leverage. (Paysign)
Plasma revenue grew 21.4% in Q2 despite fewer centres, as revenue and card loads per centre increased. Stronger use of the remaining network is helping offset the smaller footprint. (SEC)
One pharma patient-affordability customer accounted for 36% of accounts receivable at June 2026. This concentration leaves Paysign exposed to delayed or missed reimbursement from a single customer. (SEC)
Paysign had 46 fewer plasma centres year on year, after customer closures and the transfer of some centres to an operator using another provider. Continued centre losses could erode this business even if activity at remaining sites stays strong. (SEC)
Q2 included a $990,000 non-cash gain from revaluing the Gamma acquisition earn-out, and the company said this one-off benefit is included in its 2026 GAAP net-income outlook. Reported earnings therefore get a temporary lift that does not reflect recurring operating performance. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
Paysign Financial Performance
Revenues and expenses
Paysign Earnings Performance
Company profitability
Upcoming events
No upcoming events
Paysign News
AllArticlesVideos
Funds containing Paysign
Fund name | Fund size | $PAYS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.